Ken Griffin Forte Biosciences, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Forte Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,000 shares of FBRX stock, worth $590. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,000

Previous 11,700 91.45%

Holding current value

$590

Previous $9,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.48 - $0.85 $9,409 - $16,662	19,603 Added 227.49%	28,220 $19,000
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.82 $3,274 - $7,065	8,617 New	8,617 $7,000
Q2 2023 Aug 14, 2023	BUY	$0.98 - $1.11 $21,989 - $24,906	22,438 Added 33489.55%	22,505 $23,000
Q1 2023 May 15, 2023	SELL	$0.98 - $1.06 $4,411 - $4,772	-4,502 Reduced 98.53%	67 $0
Q4 2022 Feb 14, 2023	BUY	$0.96 - $1.04 $4,386 - $4,751	4,569 New	4,569 $4,000

Q2 2022 Aug 15, 2022	SELL	$1.07 - $1.55 $160,868 - $233,033	-150,344 Reduced 64.88%	81,387 $106,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.24 $20,531 - $38,008	-16,968 Reduced 6.82%	231,731 $338,000
Q4 2021 Feb 14, 2022	BUY	$2.02 - $3.36 $396,833 - $660,078	196,452 Added 376.01%	248,699 $532,000
Q3 2021 Nov 15, 2021	BUY	$2.96 - $36.67 $125,492 - $1.55 Million	42,396 Added 430.37%	52,247 $155,000
Q2 2021 Aug 16, 2021	SELL	$31.5 - $42.5 $3.32 Million - $4.48 Million	-105,342 Reduced 91.45%	9,851 $331,000
Q1 2021 May 17, 2021	SELL	$25.01 - $40.24 $6.14 Million - $9.88 Million	-245,550 Reduced 68.07%	115,193 $3.95 Million
Q4 2020 Feb 16, 2021	BUY	$28.66 - $46.79 $576,667 - $941,461	20,121 Added 5.91%	360,743 $13.1 Million
Q3 2020 Nov 16, 2020	BUY	$14.71 - $50.69 $5.01 Million - $17.3 Million	340,622 New	340,622 $16.5 Million

Others Institutions Holding FBRX

# of Institutions

Shares Held

19M

Call Options Held

Put Options Held

View Full List

About Forte Biosciences, Inc.

Ticker FBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,340,300
Market Cap $12M
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

More about FBRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account